Helicobacter pylori and Peptic Ulcer

References

• Steer H W. Surface morphology of the gastroduodenal mucosa in duodenal ulceration. Gut 1994; 25: 1203–10
   Google Scholar
• Wyatt J I, Rathbone B J, Dixon M F, Heatley R V. Campylobacter pyloridis and acid-induced gastric metaplasia in the pathogenesis of duodenitis. J Clin Pathol 1087; 40: 841–8
   Google Scholar
• Caselli M, Bovolenta M R, Aleotti E. Epithelial morphology of duodenal bulb and Campylobacter-like organisms. J Submicrosc Cytol Pathol 1989; 20: 237–42
   Google Scholar
• Price A B, Levi J, Dolby J M, et al. Campylobacter pylori in peptic ulcer disease: microbiology, pathology and scanning electron microscopy. Gut 1985; 26: 1183–8
   PubMed Web of Science ®Google Scholar
• Marshall B J, McGechie D B, Rogers P A, Clancy R J. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust 1985; 142: 439–44
   PubMed Web of Science ®Google Scholar
• Rauws E A, Langenberg W, Houthoff H J, Zanen H C, Tytgat G N. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 94: 33–40
   PubMed Web of Science ®Google Scholar
• Nensey Y M, Schubert T T, Bologna S D, Ma C K. Helicobacter pylori-negative duodenal ulcer. Am J Med 1991; 91: 15–8
   PubMed Web of Science ®Google Scholar
• Bayerdorffer E, Simon T, Bastlein C, Ottenjann R, Kasper G. Bismuth/ofloxacin combination for duodenal ulcer ‘letter’. Lancet 1987; 2: 1467–8
   PubMed Web of Science ®Google Scholar
• Graham D Y, Opekun A, Lew G M, Evans D J, Jr, Klein P D, Evans D G. Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection. Am J Gastroenterol 1990; 85: 394–8
   PubMed Web of Science ®Google Scholar
• Tytgat G NJ, Noach L A, Rauws E AJ. Helicobacter pylori infection and duodenal ulcer disease. Gastroenterol Clin N Am 1993; 22: 127–40
   PubMed Web of Science ®Google Scholar
• Niemala S, Karttunen T, Lehtola J. Campylobacter-like organisms in patients with gastric ulcer. Scand J Gastroenterol 1987; 22: 487–90
   PubMed Web of Science ®Google Scholar
• Hui W M, Lam S K, Chan P Y. Pathogenic role of Campylobacter pyloridis in gastric ulcer. J Gastroenterol Hepatol 1987; 2: 309–16
   Web of Science ®Google Scholar
• Vorohjova T, Maasroos H I, Uibo R, Wadstrom T, Wood W G, Sipponen P. Helicobacter pylori: histological and serological study on gastric and duodenal ulcer patients in Estonia. Scand J Gastroenterol 1991; 26(Suppl 186)84–9
   Google Scholar
• Ohjusa T, Okayasu I, Yamada M, et al. A high frequency of detection of Helicobacter pylori in whitish exudate of gastric ulcer. J Clin Gastroenterol 1991; 13: 649–55
   PubMed Web of Science ®Google Scholar
• Graham D Y, Lew G M, Klein P D, Evans D G, Evans D J, Jr, Saeed Z A, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study (see comments). Ann Intern Med 1992; 116: 705–8
   PubMed Web of Science ®Google Scholar
• Larkai E N, Smith J L, Lidsky M D, Graham D Y. Gastroduodenal mucosa and dyspeptic symptoms in arthritis patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82: 1153–8
   PubMed Web of Science ®Google Scholar
• Silvos G R, Levy K J, Butt J H. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 1979; 91: 517
   PubMed Web of Science ®Google Scholar
• Loeb D, Ahlquist D, Carpenter H. Role of Helicobacter pylori in non-steroidal anti-inflammatory drug (NSAID) induced gas-troduodenopathy. Am J Gastroenterol 1990; 85: 1236
   Google Scholar
• Maxton D G, Srivastava E D, Whorwell P J, Jones D M. Do non-steroidal anti-inflammatory drugs or smoking predispose to Helicobacter pylori infection?. Postgrad Med J 1990; 66: 717–9
   PubMed Web of Science ®Google Scholar
• Shallcross T M, Rahtbone B J, Wyatt J I, Heatley R V. Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 1990; 4: 515–22
   PubMed Web of Science ®Google Scholar
• Katz B, Lambert J R, Nicholson L, et al. H. pylori infection, upper gastrointestinal (UGI) symptoms and blood loss in patients with rheumatoid arthritis on NSAID. Gastroenterology 1991; 100: A96
   Google Scholar
• Laine L, Marin-Sorensen M, Weinstein W M. Helicobacter pylori prevalence and mucosal injury in gastric ulcer. Relationship to chronic nonsteroidal anti-inflammatory drug (NSAID) ingestion. Gastroenterology 1991; 100: A103
   Google Scholar
• Coghlan J G, Gilligan D, Humphries H, McKenna D, Dooley C, Sweeney E, et al. Campylobacter pylori and recurrence of duodenal ulcers: a 12 month follow-up study. Lancet 1987; ii: 1109–11
   Google Scholar
• O'Connor H. Eradication of H. pylori, therapies and clinical complications. Postgrad Med J 1992; 68: 549–57
   PubMed Web of Science ®Google Scholar
• Korman M G, Marks I N, Hunt R H, Axon A, Blaser M J, McCarthy D M, et al. Helicobacter pylori: a workshop review. Eur J Gastroenterol Hepatol 1993; 5: 963–7
   Web of Science ®Google Scholar
• Xia H, Daw M A, Sant S, Beattie S, Keane C T, O'Morain C. Clinical efficacy of triple therapy in Helicobacter pylori-associated duodenal ulcer. Eur J Gastroenterol Hepatol 1993; 5: 141–4
   Web of Science ®Google Scholar
• Xia H X, Daw M A, Beattie S, Keane C T, O'Morain C. Prevalence of metronidazole resistant H. pylori in dyspeptic patients. Ir J Med Sci 1993; 162: 91–4
   PubMed Web of Science ®Google Scholar
• European Study Group. on antibiotic susceptibility of Helicobacter pylori: results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11: 777–81
   PubMed Web of Science ®Google Scholar
• Tytgat G NJ, Noach L A. H. pylori eradication. Helicobacter pylori: basic mechanisms to clinical care, R H Hunt, G NJ Tytgat, Amsterdam 1994; 550–69
   Google Scholar
• Johnston B T, Collins J SA, Sloan J M, O'Morain C, Gilvary J, O'Connor H J. Comparison of 3, 5 and 7 day triple therapy for H. pylori eradication (Abstract). Gut 1993; 34: 537
   PubMedGoogle Scholar
• Burette A, Glupcznski Y, Prez C D. Evaluation of various multidrug eradication regimes for Helicobacter pylori. Eur J Gastroenterol Hepatol 1992; 4: 819–26
   Web of Science ®Google Scholar
• Thijs J C, Van Zwet A A, Oey H B. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993; 28: 934–8
   PubMed Web of Science ®Google Scholar
• Penston J G, Wormsley K G. Nine years of maintenance treatment with ranitidine for patients with duodenal ulcer disease. Aliment Pharmacol Ther 1992; 6: 629–45
   PubMed Web of Science ®Google Scholar
• Hentschel E, Brandstatter G, Dragosics B, Hirschl A M, Nemec H, Schutze K, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308–12
   PubMed Web of Science ®Google Scholar
• Bayerdorffer E, Mannes G A, Hochter Sommer W, Weingart J, Hatz R, Lehn N, et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand J Gastroenterol 1993; 28: 19–25, Suppl
   Web of Science ®Google Scholar
• Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991; 34: 490–6
   Google Scholar
• Megraud F, Boyanova L, Lamouliatte H. Activity of lansoprazole against Helicobacter pylori. Lancet 1991; 337: 1486, (letter)
   PubMed Web of Science ®Google Scholar
• Suerbaum S, Leying H, Klemm K, Opferkuch W. Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. Eur J Gastroenterol Hepatol 1992; 4: 697–702
   Google Scholar
• Unge P, Olsson J, Gad A, Lind T, Lonroth H, Sandmark S. Does omeprazole improve anti-microbial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis. Scand J Gastroenterol 1989; 24(Suppl 162)49–54
   Google Scholar
• Bell G D, Powell K U, Burridge S M, Bowden A N, Rameh B, Bolton G, et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med 1993; 86: 743–50
   PubMedGoogle Scholar
• Collins R, Beattie S, Xia H X, O'Morain C. Short report: high dose amoxycillin in the treatment of Helicobacter pylori-associated duodenal ulcer. Aliment Pharamcol Ther 1993; 7: 313–5
   PubMed Web of Science ®Google Scholar
• McCarthy C J, Collins R, Beattie S, Hamilton H, O'Morain C. Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics. Aliment Pharmacol Ther 1993; 7: 463–6
   PubMed Web of Science ®Google Scholar
• Logan R PH, Gummett P A, Misiewicz J J, Karim Q N, Walker M W, Baron J H. One week's anti-Helicobacterpylori treatment for duodenal ulcer. Gut 1994; 34: 15–8
   Google Scholar
• Tarnawski A, Glick M E, Stachura J, Hollander D, Gergely H. Efficacy of sucralfate and cimetidine in protection of the human gastric mucosa against alcohol injury. Am J Med 1987; 83(Suppl 3B)3107
   Web of Science ®Google Scholar
• Konturek S J, Kwiecien N, Obtulowicz W, Kopp B, Olesky J. Double-blind controlled study on the effect of sucralfate on gastric prostaglandin formation and microbleeding in normal and aspirin treated man. Gut 1986; 27: 1450–6
   PubMed Web of Science ®Google Scholar
• Koeltz H R, Halter F. Sucralfate and ranitidine in the treatment of acute duodenal ulcer. Healing and relapse. Am J Med 1989; 86(Suppl 6A)98–103
   Web of Science ®Google Scholar
• Lam S K. Implications of sucralfate-induced ulcer healing and relapse. Am J Med 1989; 86(Suppl 6A)122–6
   PubMed Web of Science ®Google Scholar
• Marks I N, Girdwood A H, Newton K A, O'Keefe S J, Marotta F, Lucke W. A maintenance regimen of sucralfate 2 g at night for reduced relapse rate in duodenal ulcer disease. A one-year follow-up study. Am J Med 1989; 86(Suppl 6A)136–40
   PubMed Web of Science ®Google Scholar
• Szabo S, Vattay P, Scarbrough E, et al. Role of vascular factors, including angiogenesis, in the mechanisms of action of sucralfate. Am J Med 1991; 91(Suppl 2A)1585–605
   Google Scholar
• Hui W M, Lam S K, Ho J, et al. Effect of sucralfate and cimetidine on duodenal ulcer associated antral gastritis and Campylobacter pylori. Am J Med 1989; 86: 60–5
   PubMed Web of Science ®Google Scholar
• Slomiany B L, Piotrowski J, Slomiany A. Effect of sucralfate on the degradation of human gastric mucous by Helicobacter pylori proteases and lipases. Am J Gastroenterol 1992; 87: 599–7
   Web of Science ®Google Scholar
• Hu W HC, Lam S K, Ho J, et al. Gastric metaplasia, Helicobacter pylori and the healing and relapse of duodenal ulcer. J Gastroenterol Hepatol 1993; 8(Suppl 2)S263
   Google Scholar
• Louw J A, Zak J, Lucke W, et al. Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates. Scand J Gastroenterol 1992; 27(Suppl 191)28–31
   Google Scholar
• Hu Lam SK, Ching C K, et al. New prospects in Helicobacter pylori eradication. Proc. 7th International Sucralfate Symposium. 1994; 43
   Google Scholar
• Aoyama N, Nakasyima J, Fujami S, et al. Eradication of Helicobacter pylori with modified triple therapy using sucralfate. Proc. 7th International Sucralfate Symposium. 1994; 46
   Google Scholar
• Stupnicki T, Taufer M, Denk H, et al. Sucralfate in combination with amoxicillin plus metronidazole for healing of duodenal ulcer and eradication of Helicobacter pylori. Follow up to one year. Proc. 7th International Sucralfate Symposium. 1994; 88
   Google Scholar
• Sung J Y, Ling T KW, Suen R, et al. Can sucralfate replace bismuth in triple therapy for the treatment of Helicobacter pylori associated duodenal ulcers?. Proc. 7th International Sucralfate Symposium. 1994; 90
   Google Scholar
• Wurzer H, Bradstatter Taufer M. Triple therapy results with sucralfate and amoxicillin plus metronidazole in the Helicobacter pylori associated duodenal ulcer. Proc. 7th International Sucralfate Symposium. 1994; 96
   Google Scholar
• Winter T, Louw J, Marks I, et al. The effect of sucralfate on Helicobacter pylori status and gastritis in duodenal ulcer patients. Proc. 7th International Sucralfate Symposium. 1994; 102
   Google Scholar
• Slomiany A, Piotrowski J, Slomiany B. Sucralfate counteracts the inhibition of gastric mucosal mucin receptor by Helicobacter pylori lipopolysaccharide. Proc. 7th International Sucralfate Symposium. 1994; 84
   Google Scholar
• Slomiany B, Piotrowski J, Majka J, Slomiany A. Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents. Proc. 7th International Sucralfate Symposium. 1994; 86
   Google Scholar